INO
Inovio Pharmaceuticals, Inc.
stockNASDAQ
inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.99 | 2026-10-14 | -18.32% | 4.805 |
| 1M | 1.24 | 2026-09-21 | -35.05% | 1.605 |
| 3M | 1.10 | 2026-07-21 | -26.78% | -1.254 |
| 6M | 1.13 | 2026-04-21 | -28.73% | 0.028 |
| 1Y | 2.33 | 2025-10-21 | -65.43% | 0.611 |
| 2Y | 5.74 | 2024-10-21 | -85.97% | — |
| 5Y | 84.48 | 2021-10-21 | -99.05% | 1.514 |
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) stock price today is $0.81, and today's volume is 10,568,499. INO is down 20.257% today. The 30 day average volume is 3.09M. INO market cap is $83.28M with 103.40M shares outstanding.